CoreFirst Bank & Trust’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$533K Buy
3,490
+40
+1% +$6.13K 0.28% 67
2025
Q4
$476K Sell
3,450
-10
-0.3% -$1.31K 0.26% 76
2025
Q3
$444K Buy
3,460
+30
+0.9% +$3.66K 0.24% 79
2025
Q2
$415K Buy
3,430
+420
+14% +$47.3K 0.23% 79
2025
Q1
$336K Buy
3,010
+700
+30% +$74.5K 0.22% 89
2024
Q4
$225K Buy
2,310
+120
+5% +$12.8K 0.13% 111
2024
Q3
$252K Sell
2,190
-9
-0.4% -$1.02K 0.15% 110
2024
Q2
$234K Hold
2,199
0.16% 112
2024
Q1
$213K Sell
2,199
-124
-5% -$12.7K 0.13% 122
2023
Q4
$235K Hold
2,323
0.16% 111
2023
Q3
$237K Sell
2,323
-7
-0.3% -$711 0.17% 109
2023
Q2
$235K Hold
2,330
0.17% 114
2023
Q1
$214K Hold
2,330
0.16% 126
2022
Q4
$211K Hold
2,330
0.16% 129
2022
Q3
$177K Hold
2,330
0.15% 131
2022
Q2
$197K Buy
2,330
+100
+4% +$8.77K 0.16% 128
2022
Q1
$196K Hold
2,230
0.13% 136
2021
Q4
$195K Sell
2,230
-500
-18% -$41.5K 0.13% 138
2021
Q3
$223K Buy
2,730
+595
+28% +$53.5K 0.15% 125
2021
Q2
$195K Hold
2,135
0.13% 138
2021
Q1
$183K Hold
2,135
0.13% 143
2020
Q4
$201K Buy
+2,135
New +$187K 0.15% 126

Other funds holding NVS

CoreFirst Bank & Trust's NVS Position: Q1 2026 in Review

CoreFirst Bank & Trust increased its Novartis (NVS) stake by 1.2% in Q1 2026, buying an estimated $6.13K and bringing the position to 3,490 shares worth $533K. The position accounts for 0.28% of the portfolio, ranked #67.

CoreFirst Bank & Trust first reported a position in NVS in Q4 2020 and has held it in 22 quarters since. 1,590 funds tracked by Wall St. Rank hold NVS as of Q1 2026.

  • CoreFirst Bank & Trust held 3,490 shares of Novartis worth $533K as of Q1 2026.
  • CoreFirst Bank & Trust bought 40 Novartis shares in Q1 2026, an estimated $6.13K.
  • Novartis made up 0.28% of CoreFirst Bank & Trust's portfolio in Q1 2026, its #67 holding.
  • CoreFirst Bank & Trust first reported a position in Novartis in Q4 2020 and has held it in 22 quarters since.
  • 1,590 funds tracked by Wall St. Rank held Novartis as of Q1 2026.

Based on CoreFirst Bank & Trust's 13F filing for Q1 2026, filed 3 Jun 2026.